Merck's Bispecific Antibody Race and Market Competition

Merck (ticker MRK) unveiled Phase 1/2 data for its PD-1/VEGF bispecific antibody 'MK-2010' (LM-299) at AACR 2026. The company acquired this asset through a licensing agreement with Lanova Medicine for an upfront payment of $588 million and potential total payments of $3.288 billion. In a cohort of previously untreated PD-L1-positive non-small cell lung cancer (NSCLC) patients, it demonstrated an objective response rate (ORR) of 55%, comparable to the efficacy of Ivonescimab, a competing drug from Akeso/Summit. However, adverse events such as hypertension and proteinuria were observed, highlighting the need for rigorous safety validation and accelerated clinical development.

A New Alternative for ROS1-Positive Lung Cancer

Nuvalent (ticker NUVL) presented clinical data for Zidesamtinib, its next-generation ROS1-targeted therapy (TKI), in patients with ROS1-positive NSCLC, garnering significant attention. In patients with resistance to existing therapies such as Augtyro or Ibtrozi, Zidesamtinib induced response rates (ORR) of 41% and 47%, respectively. Notably, the median duration of response (mDoR) in patients with prior Augtyro treatment was 15.7 months, offering a promising alternative for patients with ROS1 G2032R resistance mutations. This is significant as ROS1-positive patients account for 1-2% of all NSCLC cases, expanding treatment options for this population.

Dual-Track Innovation in Pancreatic Cancer

Innovation is also occurring in pancreatic cancer, a disease with extremely low survival rates. A Phase 1 clinical trial of 'Autogene Cevumeran' (BNT122), a personalized mRNA cancer vaccine led by Memorial Sloan Kettering Cancer Center (MSKCC), showed that 87.5% of patients exhibited a strong T-cell response, and these responders remained recurrence-free for 4-6 years after surgery. Meanwhile, Revolution Medicines (ticker RVMD) demonstrated a response rate of 47% and a 6-month progression-free survival (PFS) rate of 71% with its KRAS multi-ON inhibitor, Daraxonrasib, as a single agent, opening the door to precision medicine in pancreatic cancer.

Next-Generation ADCs with Enhanced Safety and Selectivity

In the antibody-drug conjugate (ADC) field, new drugs that control side effects and enhance selectivity have emerged. Qilu Pharmaceutical, a Chinese company, reported an objective response rate of 50% in platinum-resistant ovarian cancer patients in a Phase 1 clinical trial of its Claudin6 (CLDN6)-targeting ADC, 'QLS5132,' with no severe adverse events such as pulmonary edema, paving the way for Phase 3 trials. Promatix Biosciences, a UK-based company, presented preclinical data for 'PBS293,' a dual ADC based on an 'AND gate' that simultaneously targets EGFR and EphA2 on cancer cells, demonstrating the potential of next-generation technology to deliver effective drugs precisely.

Partnerships for Genomic Analysis Innovation

Partnerships for genomic analysis innovation were also announced at the conference. PacBio (ticker PACB) and Covaris announced a workflow for analyzing FFPE samples that combines high-precision long-read sequencing technology with specialized extraction equipment. This allows for the extraction of high-quality data from FFPE samples of cancer patients, which are often difficult to analyze, enabling the detection of 2-3 times more genomic structural variations. This collaboration is expected to significantly contribute to the re-analysis of clinical samples accumulated over the past decades, the discovery of new biomarkers, and the maximization of the efficacy of cancer treatment for individual patients.